ArticleFrontiers in immunology2018
Inducible T-Cell Co-Stimulator Impacts Chronic Graft-Versus-Host Disease by Regulating Both Pathogenic and Regulatory T Cells.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Dimethyl fumarate ameliorates chronic graft-versus-host disease by inhibiting Tfh differentiation via Nrf2.Leukemia · 2025Article
- Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD.Blood advances · 2023Article
- ICOS costimulation is indispensable for the differentiation of T follicular regulatory cells.Life science alliance · 2023Article
- TCF-1 Is Required for CD4 T Cell Persistence Functions during AlloImmunity.International journal of molecular sciences · 2023Article
- Divergent CD4Frontiers in immunology · 2023Article
- ICOS immunoPET enables visualization of activated T cells and early diagnosis of murine acute gastrointestinal GvHD.Blood advances · 2022Article
- CD1d-independent NK1.1Frontiers in immunology · 2022Article
- Current Concepts and Advances in Graft-Versus-Host Disease Immunology.Annual review of immunology · 2021Article
- CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade.Cancers · 2021Article
- XBP-1s Promotes B Cell Pathogenicity in Chronic GVHD by Restraining the Activity of Regulated IRE-1α-Dependent Decay.Frontiers in immunology · 2021Article
- LPSFrontiers in immunology · 2021Article
- Loss of Phosphatidylinositol 3-Kinase Activity in Regulatory T Cells Leads to Neuronal Inflammation.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- PDL1 blockage increases fetal resorption and Tfr cells but does not affect Tfh/Tfr ratio and B-cell maturation during allogeneic pregnancy.Cell death & disease · 2020Article
- Progress of cGVHD pathogenesis from the perspective of B cells.Blood science (Baltimore, Md.) · 2019Article
- Cutting Edge: ICOS-Deficient Regulatory T Cells Display Normal Induction ofJournal of immunology (Baltimore, Md. : 1950) · 2019Article
- Developing role of B cells in the pathogenesis and treatment of chronic GVHD.British journal of haematology · 2019Review
- Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice.Blood · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
Abstract
The incidence of chronic graft-versus-host disease (cGVHD) is on the rise and still the major cause of morbidity and mortality among patients after allogeneic hematopoietic stem cell transplantation (HCT). Both donor T and B cells contribute to the pathogenesis of cGVHD. Inducible T-cell co-stimulator (ICOS), a potent co-stimulatory receptor, plays a key role in T-cell activation and differentiation. Yet, how ICOS regulates the development of cGVHD is not well understood. Here, we investigated the role of ICOS in cGVHD pathogenesis using mice with germline or regulatory T cell (Treg)-specific ICOS deficiency. The recipients of ICOS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.